Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 488Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 421Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 232Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

enfortumab vedotin 2pembrolizumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Bladder Cancer × Genitourinary × Clear all
NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
41 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting
224 enrolled
Genitourinary

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡